DENTSPLY International Inc. — Q1 2012 Form 10-Q Summary
Business context and reporting period
The filing covers the three months ended March 31, 2012. DENTSPLY International, the predecessor company referenced in the filing metadata as DENTSPLY SIRONA Inc., manufactured and distributed dental and healthcare products in more than 120 countries. Professional dental products represented approximately 89% of sales. Results include the Astra Tech acquisition, completed August 31, 2011.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $716.4 million | $570.5 million | +25.6% |
| Net sales excluding precious metals | $665.6 million | $527.0 million | +26.3% |
| Gross profit | $392.8 million | $300.0 million | +30.9% |
| Gross margin | 54.8% | 52.6% | +2.2 pts |
| Gross margin excluding precious metals | 59.0% | 56.9% | +2.1 pts |
| Operating income | $87.2 million | $98.6 million | -11.6% |
| Operating margin | 12.2% | 17.3% | -5.1 pts |
| Net income attributable to DENTSPLY | $53.3 million | $69.1 million | -22.9% |
| Diluted EPS | $0.37 | $0.48 | -$0.11 |
| Operating cash flow | $20.0 million | $44.7 million | -55.4% |
SG&A increased 51.6% to $304.4 million, including higher Astra Tech operating expenses, $12.0 million of amortization primarily related to acquired intangibles, and $6.4 million of integration costs. Restructuring and other costs were $1.2 million versus $0.6 million in the prior-year quarter. Net interest expense increased to $13.5 million from $4.5 million because of acquisition-related debt. The effective tax rate declined to 20.1% from 25.2%. Management reported adjusted non-GAAP diluted EPS of $0.52 versus $0.50, excluding specified acquisition, amortization, restructuring, orthodontic continuity, affiliate fair-value and tax items.
Cash and equivalents were $67.3 million at March 31, 2012, down from $77.1 million at December 31, 2011. Total debt, including current maturities, was approximately $1.77 billion on the balance sheet, while the estimated fair value of total long-term debt including current maturities was $1.51 billion. Total debt-to-capitalization was 46.4%, compared with 48.4% at year-end. The company had $541.6 million of unused revolving and uncommitted credit capacity and was in compliance with debt covenants. Capital expenditures were $18.6 million.
Material changes versus the prior comparable period
- Reported sales growth was primarily acquisition-driven: acquisition growth excluding precious metal content was 27.2%, internal growth was 1.1%, and currency translation reduced growth by 2.0%.
- Astra Tech drove substantial growth in the Implants/Endodontics/Healthcare/Pacific Rim segment, where sales excluding precious metals increased 82.7% and segment operating income increased 22.4%.
- Orthodontics/Canada/Mexico/Japan sales excluding precious metals declined 18.3% and segment operating income declined 95.7%, primarily because of supply disruptions following the March 2011 Japan natural disaster.
- Gross margin improved because of product mix and pricing, but operating and net margins declined because of acquisition-related amortization and costs, integration spending, higher SG&A, increased interest expense, and a $4.2 million after-tax loss from the DIO investment.
- Operating cash flow declined as net income fell and working-capital investment increased, particularly in inventory, receivables and prepaid assets. Reported inventory days increased by 10 days and receivable days by 4 days versus December 31, 2011, including acquisitions.
- Other comprehensive income was $124.3 million, principally reflecting foreign-currency translation gains and unrealized gains on available-for-sale securities; this was not equivalent to operating earnings or cash flow.
Guidance, outlook, risks and unusual items
- Management’s long-term internal-growth target is 4% to 6%, but it expected 2012 could fall below that range because of European economic uncertainty and global conditions.
- The Orthodontics supply disruption reduced first-quarter earnings by approximately $0.04 to $0.05 per diluted share. Management expected improvement in the second quarter and a positive year-over-year impact in the third quarter, while describing the recovery as a multiyear process.
- Management continued Astra Tech integration and restructuring initiatives, including facility consolidation and a combined U.S. dental implant organization.
- Key exposures include foreign-currency movements, interest rates, commodity prices, acquisition integration, regulatory and competitive conditions, product innovation, and economic weakness in Europe. More than 65% of sales were outside the United States.
- Pending Cavitron-related litigation remained unresolved, and a reasonable possible loss range could not be estimated. An unfavorable outcome could materially affect results.
- The company held $160.3 million of precious metals on consignment. Loss of these arrangements could require third-party financing to fund required inventory.
- Goodwill and acquired intangible valuations remained subject to finalization of the Astra Tech purchase-price allocation. The filing states that related adjustments could be significant.
- Potential tax settlements or statute expirations during the following 12 months could affect approximately $7.5 million of unrecognized tax benefits.
Important facts for investors to verify
- Reconcile reported sales growth and adjusted growth with the continuing contribution, costs and integration progress of Astra Tech.
- Monitor Orthodontics supply recovery, Japan-related disruption, and whether management’s stated third-quarter improvement occurs.
- Assess whether SG&A, amortization, integration spending and interest costs normalize sufficiently to restore operating leverage.
- Review working-capital trends, especially inventory and receivables, and their effect on cash conversion.
- Verify debt maturities, refinancing needs, covenant compliance and available liquidity, including the $250 million 364-day facility expiring August 29, 2012.
- Evaluate exposure to foreign-exchange hedge liabilities, commodity prices, precious-metal consignment arrangements and DIO-related fair-value volatility.
- Track the Cavitron litigation, Astra Tech purchase-price allocation, goodwill impairment testing and contingent acquisition consideration.